JP2018118992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018118992A5 JP2018118992A5 JP2018070780A JP2018070780A JP2018118992A5 JP 2018118992 A5 JP2018118992 A5 JP 2018118992A5 JP 2018070780 A JP2018070780 A JP 2018070780A JP 2018070780 A JP2018070780 A JP 2018070780A JP 2018118992 A5 JP2018118992 A5 JP 2018118992A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- azetidin
- pyrimidin
- pyrazol
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 bromo, cyano, methyl Chemical group 0.000 claims 183
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 119
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 54
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 49
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- IWEBPQGVVUAHKX-UHFFFAOYSA-N 2-[3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-1-[1-[5-(trifluoromethyl)pyrazine-2-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1=NC(C(F)(F)F)=CN=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 IWEBPQGVVUAHKX-UHFFFAOYSA-N 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- INSWZAQOISIYDT-UHFFFAOYSA-N imidazo[1,2-a]pyrimidine Chemical group C1=CC=NC2=NC=CN21 INSWZAQOISIYDT-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000004227 1,3-benzoxazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)OC2=C1[H] 0.000 claims 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- WWCQUYYZUBAXIG-UHFFFAOYSA-N 2-[1-(1-benzoylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC=C1 WWCQUYYZUBAXIG-UHFFFAOYSA-N 0.000 claims 1
- KWFYWZIQQLCRFX-UHFFFAOYSA-N 2-[1-(1-cyclohexylsulfonylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1CCCCC1 KWFYWZIQQLCRFX-UHFFFAOYSA-N 0.000 claims 1
- MVGIEAHSBOJVAK-UHFFFAOYSA-N 2-[1-(1-cyclopentylsulfonylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1CCCC1 MVGIEAHSBOJVAK-UHFFFAOYSA-N 0.000 claims 1
- YBLNSIVEOFFIIM-UHFFFAOYSA-N 2-[1-(1-cyclopropylsulfonylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1CC1 YBLNSIVEOFFIIM-UHFFFAOYSA-N 0.000 claims 1
- QEGZRROKGOQUMC-UHFFFAOYSA-N 2-[1-(1-methylsulfonylpiperidin-4-yl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CN(S(=O)(=O)C)CCC1N1CC(CC#N)(N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)C1 QEGZRROKGOQUMC-UHFFFAOYSA-N 0.000 claims 1
- WQOAJTQMCGXFLM-UHFFFAOYSA-N 2-[1-(1-methylsulfonylpiperidin-4-yl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CN(S(=O)(=O)C)CCC1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)C1 WQOAJTQMCGXFLM-UHFFFAOYSA-N 0.000 claims 1
- UVJGCVACFIBHKR-UHFFFAOYSA-N 2-[1-(1-methylsulfonylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CN(S(=O)(=O)C)CCC1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C1 UVJGCVACFIBHKR-UHFFFAOYSA-N 0.000 claims 1
- UMMXSJIRXBRCLD-UHFFFAOYSA-N 2-[1-(1-propan-2-ylsulfonylpiperidin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CN(S(=O)(=O)C(C)C)CCC1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C1 UMMXSJIRXBRCLD-UHFFFAOYSA-N 0.000 claims 1
- SKJYTNXCNZQSIF-UHFFFAOYSA-N 2-[1-[1-(1,2-dimethylimidazol-4-yl)sulfonylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1C(C)=NC(S(=O)(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 SKJYTNXCNZQSIF-UHFFFAOYSA-N 0.000 claims 1
- PXSWCPXQUZLXKG-UHFFFAOYSA-N 2-[1-[1-(1,3-oxazole-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=NC=CO1 PXSWCPXQUZLXKG-UHFFFAOYSA-N 0.000 claims 1
- NDRFHXUVPHBSHC-UHFFFAOYSA-N 2-[1-[1-(1-benzofuran-2-ylmethyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1N(C2CCN(CC=3OC4=CC=CC=C4C=3)CC2)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 NDRFHXUVPHBSHC-UHFFFAOYSA-N 0.000 claims 1
- CMBZNHSLRJYIHI-UHFFFAOYSA-N 2-[1-[1-(1-benzothiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=C2SC(C(N3CCC(CC3)N3CC(CC#N)(C3)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)=O)=CC2=C1 CMBZNHSLRJYIHI-UHFFFAOYSA-N 0.000 claims 1
- ZQMJYMBEZCWGSX-UHFFFAOYSA-N 2-[1-[1-(1-benzothiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=C2C(C(N3CCC(CC3)N3CC(CC#N)(C3)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)=O)=CSC2=C1 ZQMJYMBEZCWGSX-UHFFFAOYSA-N 0.000 claims 1
- CTKQRINFSGLLTR-UHFFFAOYSA-N 2-[1-[1-(1-methylpyrazol-3-yl)sulfonylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1C=CC(S(=O)(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 CTKQRINFSGLLTR-UHFFFAOYSA-N 0.000 claims 1
- VQUVLTANUQOWGQ-UHFFFAOYSA-N 2-[1-[1-(1-phenylcyclopropanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1(C=2C=CC=CC=2)CC1 VQUVLTANUQOWGQ-UHFFFAOYSA-N 0.000 claims 1
- CRJBQWSTISJUDX-UHFFFAOYSA-N 2-[1-[1-(2,3-difluorobenzoyl)piperidin-4-yl]-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)=C1F CRJBQWSTISJUDX-UHFFFAOYSA-N 0.000 claims 1
- WWXJDLQTHPTLSY-UHFFFAOYSA-N 2-[1-[1-(2,3-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1F WWXJDLQTHPTLSY-UHFFFAOYSA-N 0.000 claims 1
- ZQUFAQRNGXJXKU-UHFFFAOYSA-N 2-[1-[1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1N(C2CCN(CC=3C=C4OCCOC4=CC=3)CC2)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 ZQUFAQRNGXJXKU-UHFFFAOYSA-N 0.000 claims 1
- GXXIRGRFCRZVEY-UHFFFAOYSA-N 2-[1-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 GXXIRGRFCRZVEY-UHFFFAOYSA-N 0.000 claims 1
- RJVFCWDKCFHFCU-UHFFFAOYSA-N 2-[1-[1-(2,5-dichlorothiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C(Cl)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1Cl RJVFCWDKCFHFCU-UHFFFAOYSA-N 0.000 claims 1
- OBPSLGZMVKIXGQ-UHFFFAOYSA-N 2-[1-[1-(2,5-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 OBPSLGZMVKIXGQ-UHFFFAOYSA-N 0.000 claims 1
- SMVCBLYKCXTELF-UHFFFAOYSA-N 2-[1-[1-(2,5-dimethylfuran-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound O1C(C)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1C SMVCBLYKCXTELF-UHFFFAOYSA-N 0.000 claims 1
- SBHHEMKZMHFDBK-UHFFFAOYSA-N 2-[1-[1-(2,6-difluoro-4-pyridin-3-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C(F)=C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C(F)=CC=1C1=CC=CN=C1 SBHHEMKZMHFDBK-UHFFFAOYSA-N 0.000 claims 1
- NHRDJCJAZPXGHO-UHFFFAOYSA-N 2-[1-[1-(2,6-difluorobenzoyl)piperidin-4-yl]-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 NHRDJCJAZPXGHO-UHFFFAOYSA-N 0.000 claims 1
- ZMLIEXXBMBCQOG-UHFFFAOYSA-N 2-[1-[1-(2,6-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 ZMLIEXXBMBCQOG-UHFFFAOYSA-N 0.000 claims 1
- REWRZUYGBLZJHU-UHFFFAOYSA-N 2-[1-[1-(2-bromothiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1Br REWRZUYGBLZJHU-UHFFFAOYSA-N 0.000 claims 1
- JPXPFBBAKOKSRT-UHFFFAOYSA-N 2-[1-[1-(2-chloro-6-methoxypyridine-4-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=NC(OC)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 JPXPFBBAKOKSRT-UHFFFAOYSA-N 0.000 claims 1
- DMDURKJRBQMCDG-UHFFFAOYSA-N 2-[1-[1-(2-fluoro-4-hydroxybenzoyl)piperidin-4-yl]-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(O)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 DMDURKJRBQMCDG-UHFFFAOYSA-N 0.000 claims 1
- MFJNAWBKFSYMLB-UHFFFAOYSA-N 2-[1-[1-(2-fluoro-4-hydroxybenzoyl)piperidin-4-yl]-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(O)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 MFJNAWBKFSYMLB-UHFFFAOYSA-N 0.000 claims 1
- KPIOSKYFOLZVGZ-UHFFFAOYSA-N 2-[1-[1-(2-fluoro-4-pyridin-3-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C(F)=CC=1C1=CC=CN=C1 KPIOSKYFOLZVGZ-UHFFFAOYSA-N 0.000 claims 1
- BRGQAIVRMIFYPX-UHFFFAOYSA-N 2-[1-[1-(2-fluoro-5-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC=C(F)C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 BRGQAIVRMIFYPX-UHFFFAOYSA-N 0.000 claims 1
- USZNWFJQMFPPHA-UHFFFAOYSA-N 2-[1-[1-(2-fluoro-6-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 USZNWFJQMFPPHA-UHFFFAOYSA-N 0.000 claims 1
- QTERYNFOEROINI-UHFFFAOYSA-N 2-[1-[1-(2-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 QTERYNFOEROINI-UHFFFAOYSA-N 0.000 claims 1
- UIZMYHBGWDBHMQ-UHFFFAOYSA-N 2-[1-[1-(2-methylpyrazol-3-yl)sulfonylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1N=CC=C1S(=O)(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 UIZMYHBGWDBHMQ-UHFFFAOYSA-N 0.000 claims 1
- PEVDFLNZLMHOII-UHFFFAOYSA-N 2-[1-[1-(2-phenylacetyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)CC1=CC=CC=C1 PEVDFLNZLMHOII-UHFFFAOYSA-N 0.000 claims 1
- JYTXMAGXSCRQTE-UHFFFAOYSA-N 2-[1-[1-(3,4-difluorobenzoyl)piperidin-4-yl]-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 JYTXMAGXSCRQTE-UHFFFAOYSA-N 0.000 claims 1
- UDQGRPPPPIRJIS-UHFFFAOYSA-N 2-[1-[1-(3,4-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 UDQGRPPPPIRJIS-UHFFFAOYSA-N 0.000 claims 1
- DLIUAQISEFIHQE-UHFFFAOYSA-N 2-[1-[1-(3,5-dibromo-4-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(Br)C(OC)=C(Br)C=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 DLIUAQISEFIHQE-UHFFFAOYSA-N 0.000 claims 1
- RLGJETWHGLSOSB-UHFFFAOYSA-N 2-[1-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 RLGJETWHGLSOSB-UHFFFAOYSA-N 0.000 claims 1
- CQHRLVINYXZBOO-UHFFFAOYSA-N 2-[1-[1-(3,5-difluoropyridine-4-carbonyl)piperidin-4-yl]-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 CQHRLVINYXZBOO-UHFFFAOYSA-N 0.000 claims 1
- LVWFVGNNMGWEOB-UHFFFAOYSA-N 2-[1-[1-(3,5-difluoropyridine-4-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 LVWFVGNNMGWEOB-UHFFFAOYSA-N 0.000 claims 1
- PELUGJMVZMKGFV-UHFFFAOYSA-N 2-[1-[1-(3,5-dimethoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC(OC)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 PELUGJMVZMKGFV-UHFFFAOYSA-N 0.000 claims 1
- CPDPOYFGOATSMC-UHFFFAOYSA-N 2-[1-[1-(3-bromo-5-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(Br)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 CPDPOYFGOATSMC-UHFFFAOYSA-N 0.000 claims 1
- YYCCMMSVRTTYMR-UHFFFAOYSA-N 2-[1-[1-(3-bromobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound BrC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 YYCCMMSVRTTYMR-UHFFFAOYSA-N 0.000 claims 1
- PONHYSCYLJVGGT-UHFFFAOYSA-N 2-[1-[1-(3-chloro-4-fluoro-1-benzothiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC=1C=2C(F)=CC=CC=2SC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 PONHYSCYLJVGGT-UHFFFAOYSA-N 0.000 claims 1
- PWIXLGJSUQATBT-UHFFFAOYSA-N 2-[1-[1-(3-chloro-4-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 PWIXLGJSUQATBT-UHFFFAOYSA-N 0.000 claims 1
- XVKIJNUDBATXCI-UHFFFAOYSA-N 2-[1-[1-(3-chloro-4-hydroxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(Cl)C(O)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 XVKIJNUDBATXCI-UHFFFAOYSA-N 0.000 claims 1
- ROZOGAUDFBWABS-UHFFFAOYSA-N 2-[1-[1-(3-chloro-5-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(Cl)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ROZOGAUDFBWABS-UHFFFAOYSA-N 0.000 claims 1
- GPKMLSFODGOOPI-UHFFFAOYSA-N 2-[1-[1-(3-chloro-6-fluoro-1-benzothiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C2=CC(F)=CC=C2C(Cl)=C1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 GPKMLSFODGOOPI-UHFFFAOYSA-N 0.000 claims 1
- YAEMRFMASWMAIB-UHFFFAOYSA-N 2-[1-[1-(3-chlorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 YAEMRFMASWMAIB-UHFFFAOYSA-N 0.000 claims 1
- YKJZKTRGAOWQGE-UHFFFAOYSA-N 2-[1-[1-(3-chlorothiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CSC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1Cl YKJZKTRGAOWQGE-UHFFFAOYSA-N 0.000 claims 1
- FSMLEFFQVXGPGK-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-hydroxybenzoyl)piperidin-4-yl]-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(O)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 FSMLEFFQVXGPGK-UHFFFAOYSA-N 0.000 claims 1
- FEHGTLOEQXJQIQ-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-hydroxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(O)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 FEHGTLOEQXJQIQ-UHFFFAOYSA-N 0.000 claims 1
- GLVCJQZBMGIXEU-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-isoquinolin-5-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C3=CC=NC=C3C=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 GLVCJQZBMGIXEU-UHFFFAOYSA-N 0.000 claims 1
- XCNBPIQLDHQRRB-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-isoquinolin-6-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C=C3C=CN=CC3=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 XCNBPIQLDHQRRB-UHFFFAOYSA-N 0.000 claims 1
- MYHGFCOEZBQMGW-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-isoquinolin-7-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C=C3C=NC=CC3=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 MYHGFCOEZBQMGW-UHFFFAOYSA-N 0.000 claims 1
- KXEMJYMPUSGUCE-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-isoquinolin-8-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C3=CN=CC=C3C=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 KXEMJYMPUSGUCE-UHFFFAOYSA-N 0.000 claims 1
- DXOJEJQDPZHDFN-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(OC)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 DXOJEJQDPZHDFN-UHFFFAOYSA-N 0.000 claims 1
- MUFKQBYNDBPEJX-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(C)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 MUFKQBYNDBPEJX-UHFFFAOYSA-N 0.000 claims 1
- OTDXPDMLAISOPA-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-methylsulfanylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(SC)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 OTDXPDMLAISOPA-UHFFFAOYSA-N 0.000 claims 1
- OGWNCQSRNNZHNT-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-pyridin-3-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=C1C1=CC=CN=C1 OGWNCQSRNNZHNT-UHFFFAOYSA-N 0.000 claims 1
- WHGDXCBTRUREHN-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-quinolin-5-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C3=CC=CN=C3C=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 WHGDXCBTRUREHN-UHFFFAOYSA-N 0.000 claims 1
- WZAHZXZSJCINDG-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-quinolin-6-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C=C3C=CC=NC3=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 WZAHZXZSJCINDG-UHFFFAOYSA-N 0.000 claims 1
- PDTKIVOSSUKDHU-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-quinolin-7-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C=C3N=CC=CC3=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 PDTKIVOSSUKDHU-UHFFFAOYSA-N 0.000 claims 1
- XGMWXHBQIJOUSF-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-4-quinolin-8-ylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2C3=NC=CC=C3C=CC=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 XGMWXHBQIJOUSF-UHFFFAOYSA-N 0.000 claims 1
- IJRZRTMNZPOXPD-UHFFFAOYSA-N 2-[1-[1-(3-fluoro-5-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 IJRZRTMNZPOXPD-UHFFFAOYSA-N 0.000 claims 1
- UGNHTUCXHZUOAH-UHFFFAOYSA-N 2-[1-[1-(3-fluorobenzoyl)-2-methylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC(F)=C1 UGNHTUCXHZUOAH-UHFFFAOYSA-N 0.000 claims 1
- JEZSEZLTLKWQGU-UHFFFAOYSA-N 2-[1-[1-(3-fluorobenzoyl)-4-methylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(C)(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC(F)=C1 JEZSEZLTLKWQGU-UHFFFAOYSA-N 0.000 claims 1
- YWETXYVWGHGDPH-UHFFFAOYSA-N 2-[1-[1-(3-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 YWETXYVWGHGDPH-UHFFFAOYSA-N 0.000 claims 1
- LHBDJRDLYJGHQC-UHFFFAOYSA-N 2-[1-[1-(3-fluoropyridine-4-carbonyl)piperidin-4-yl]-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 LHBDJRDLYJGHQC-UHFFFAOYSA-N 0.000 claims 1
- FUMFZXHUPAWMJB-UHFFFAOYSA-N 2-[1-[1-(3-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 FUMFZXHUPAWMJB-UHFFFAOYSA-N 0.000 claims 1
- FKBKNZXJZQXGLP-UHFFFAOYSA-N 2-[1-[1-(3-methoxycyclohexanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1C(OC)CCCC1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 FKBKNZXJZQXGLP-UHFFFAOYSA-N 0.000 claims 1
- SHVUHXZKTMVSJM-UHFFFAOYSA-N 2-[1-[1-(3-methoxythiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CSC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1OC SHVUHXZKTMVSJM-UHFFFAOYSA-N 0.000 claims 1
- IDFGKBFSZUCHST-UHFFFAOYSA-N 2-[1-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CSC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1C IDFGKBFSZUCHST-UHFFFAOYSA-N 0.000 claims 1
- CEDGQLZBXNDTRM-UHFFFAOYSA-N 2-[1-[1-(4,4-difluorocyclohexanecarbonyl)-2-methylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1CCC(F)(F)CC1 CEDGQLZBXNDTRM-UHFFFAOYSA-N 0.000 claims 1
- GQMRHFSVNVKOJI-UHFFFAOYSA-N 2-[1-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(F)(F)CCC1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 GQMRHFSVNVKOJI-UHFFFAOYSA-N 0.000 claims 1
- GYKTUKONDFVHDX-UHFFFAOYSA-N 2-[1-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=C2NC=CC2=C1C(=C1)C=NN1C(C1)(CC#N)CN1C(CC1)CCN1C(=O)C1CCC(F)(F)CC1 GYKTUKONDFVHDX-UHFFFAOYSA-N 0.000 claims 1
- HDSRMYGFRHGZPX-UHFFFAOYSA-N 2-[1-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(F)(F)CCC1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 HDSRMYGFRHGZPX-UHFFFAOYSA-N 0.000 claims 1
- WDOHYLSCXALEBN-UHFFFAOYSA-N 2-[1-[1-(4-chloro-3-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(Cl)C(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WDOHYLSCXALEBN-UHFFFAOYSA-N 0.000 claims 1
- XXZUBCPXZFVIPQ-UHFFFAOYSA-N 2-[1-[1-(4-fluoro-2-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 XXZUBCPXZFVIPQ-UHFFFAOYSA-N 0.000 claims 1
- DHLKKOHJLVYBHE-UHFFFAOYSA-N 2-[1-[1-(4-fluoro-3-hydroxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(O)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 DHLKKOHJLVYBHE-UHFFFAOYSA-N 0.000 claims 1
- GVQJMBULVQMONV-UHFFFAOYSA-N 2-[1-[1-(4-fluoro-3-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(OC)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 GVQJMBULVQMONV-UHFFFAOYSA-N 0.000 claims 1
- AADHVPUFTNZHCH-UHFFFAOYSA-N 2-[1-[1-(4-fluorobenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 AADHVPUFTNZHCH-UHFFFAOYSA-N 0.000 claims 1
- DRHXPCGMXRBSJR-UHFFFAOYSA-N 2-[1-[1-(4-methoxythiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CSC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 DRHXPCGMXRBSJR-UHFFFAOYSA-N 0.000 claims 1
- OLJTZRVGXSGXQJ-UHFFFAOYSA-N 2-[1-[1-(4-methylthiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC1=CSC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 OLJTZRVGXSGXQJ-UHFFFAOYSA-N 0.000 claims 1
- DUKGQZXOHHYYOE-UHFFFAOYSA-N 2-[1-[1-(4-phenylbenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 DUKGQZXOHHYYOE-UHFFFAOYSA-N 0.000 claims 1
- PVZUXNMMBYHDFS-UHFFFAOYSA-N 2-[1-[1-(4-phenylcyclohexanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C(CC1)CCC1C1=CC=CC=C1 PVZUXNMMBYHDFS-UHFFFAOYSA-N 0.000 claims 1
- GOLMFUVOUGPIMU-UHFFFAOYSA-N 2-[1-[1-(5-chloro-4-methoxythiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=C(Cl)SC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 GOLMFUVOUGPIMU-UHFFFAOYSA-N 0.000 claims 1
- KACSUSIXJYMTAH-UHFFFAOYSA-N 2-[1-[1-(5-chlorothiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C(Cl)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KACSUSIXJYMTAH-UHFFFAOYSA-N 0.000 claims 1
- KERVZMOHTHESEC-UHFFFAOYSA-N 2-[1-[1-(5-fluoro-2-methoxybenzoyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC=C(F)C=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KERVZMOHTHESEC-UHFFFAOYSA-N 0.000 claims 1
- SIPLUFHWHHQVCL-UHFFFAOYSA-N 2-[1-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C(C)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 SIPLUFHWHHQVCL-UHFFFAOYSA-N 0.000 claims 1
- HZOBANCSUKNMLB-UHFFFAOYSA-N 2-[1-[1-(5-methylthiophene-3-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound S1C(C)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 HZOBANCSUKNMLB-UHFFFAOYSA-N 0.000 claims 1
- CQYBEJRPYMDIOE-UHFFFAOYSA-N 2-[1-[1-(6-chloropyridine-2-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 CQYBEJRPYMDIOE-UHFFFAOYSA-N 0.000 claims 1
- QIESCFKEOOZXCO-UHFFFAOYSA-N 2-[1-[1-(cycloheptanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1CCCCCC1 QIESCFKEOOZXCO-UHFFFAOYSA-N 0.000 claims 1
- DLPLELNVVGUNFT-UHFFFAOYSA-N 2-[1-[1-(cyclohexanecarbonyl)-4-methylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(C)(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1CCCCC1 DLPLELNVVGUNFT-UHFFFAOYSA-N 0.000 claims 1
- CNXZTEGPBSMDDA-UHFFFAOYSA-N 2-[1-[1-(cyclohexanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1CCCCC1 CNXZTEGPBSMDDA-UHFFFAOYSA-N 0.000 claims 1
- HPACOSDHEUMMSF-UHFFFAOYSA-N 2-[1-[1-(cyclopentanecarbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1CCCC1 HPACOSDHEUMMSF-UHFFFAOYSA-N 0.000 claims 1
- HHAUIQVPGMLYMC-UHFFFAOYSA-N 2-[1-[1-(naphthalene-1-carbonyl)piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=C2C(C(N3CCC(CC3)N3CC(CC#N)(C3)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)=O)=CC=CC2=C1 HHAUIQVPGMLYMC-UHFFFAOYSA-N 0.000 claims 1
- YRHXUFFDQFEJCC-UHFFFAOYSA-N 2-[1-[1-(pyrazine-2-carbonyl)piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound N1=C(C=NC=C1)C(=O)N1CCC(CC1)N1CC(C1)(N1N=CC(=C1)C=1C2=C(N=CN=1)NC=C2)CC#N YRHXUFFDQFEJCC-UHFFFAOYSA-N 0.000 claims 1
- GUGGWJYKSFKRDX-UHFFFAOYSA-N 2-[1-[1-[(2,3-dichlorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CC=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1Cl GUGGWJYKSFKRDX-UHFFFAOYSA-N 0.000 claims 1
- PXTAZAMVQUUMPE-UHFFFAOYSA-N 2-[1-[1-[(2,4-difluorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(F)=CC=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 PXTAZAMVQUUMPE-UHFFFAOYSA-N 0.000 claims 1
- OXSPFXRDVRBQNS-UHFFFAOYSA-N 2-[1-[1-[(2,6-dibromopyridin-4-yl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound BrC1=NC(Br)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 OXSPFXRDVRBQNS-UHFFFAOYSA-N 0.000 claims 1
- VIEXTUGLTBXVPQ-UHFFFAOYSA-N 2-[1-[1-[(2-bromopyridin-4-yl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=NC(Br)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 VIEXTUGLTBXVPQ-UHFFFAOYSA-N 0.000 claims 1
- GOLJRHSZAPEKIT-UHFFFAOYSA-N 2-[1-[1-[(2-chloro-3,4-dimethoxyphenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=C(OC)C(OC)=CC=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 GOLJRHSZAPEKIT-UHFFFAOYSA-N 0.000 claims 1
- PHQCGVFDGCIHIR-UHFFFAOYSA-N 2-[1-[1-[(2-chloro-6-fluorophenyl)methyl]-2-methylpiperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1CC1=C(F)C=CC=C1Cl PHQCGVFDGCIHIR-UHFFFAOYSA-N 0.000 claims 1
- GSVZUHXRYCYHON-UHFFFAOYSA-N 2-[1-[1-[(2-chloro-6-fluorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(Cl)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 GSVZUHXRYCYHON-UHFFFAOYSA-N 0.000 claims 1
- VZYDRNUBBJZACH-UHFFFAOYSA-N 2-[1-[1-[(2-chloroquinolin-3-yl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=NC2=CC=CC=C2C=C1CN(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 VZYDRNUBBJZACH-UHFFFAOYSA-N 0.000 claims 1
- CUOPRISSKJCUKG-UHFFFAOYSA-N 2-[1-[1-[(2-fluoro-6-methoxyphenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1=CC=CC(F)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 CUOPRISSKJCUKG-UHFFFAOYSA-N 0.000 claims 1
- WAQCFGIFSZUCPG-UHFFFAOYSA-N 2-[1-[1-[(3,5-dichlorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CC(Cl)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WAQCFGIFSZUCPG-UHFFFAOYSA-N 0.000 claims 1
- VFBISBTYIXQZRX-UHFFFAOYSA-N 2-[1-[1-[(3,5-dichloropyridin-4-yl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CN=CC(Cl)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 VFBISBTYIXQZRX-UHFFFAOYSA-N 0.000 claims 1
- SWQZXCPMESABJL-UHFFFAOYSA-N 2-[1-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(F)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 SWQZXCPMESABJL-UHFFFAOYSA-N 0.000 claims 1
- CHQKZKZKVPCOPD-UHFFFAOYSA-N 2-[1-[1-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC1=NOC(C)=C1S(=O)(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 CHQKZKZKVPCOPD-UHFFFAOYSA-N 0.000 claims 1
- RGOVMAWIJMEFFV-UHFFFAOYSA-N 2-[1-[1-[(3-chloro-2,6-difluorophenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(Cl)C(F)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 RGOVMAWIJMEFFV-UHFFFAOYSA-N 0.000 claims 1
- YUJWHVPMAKCLQL-UHFFFAOYSA-N 2-[1-[1-[(3-phenoxyphenyl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1C(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CN1C(CC1)CCN1CC(C=1)=CC=CC=1OC1=CC=CC=C1 YUJWHVPMAKCLQL-UHFFFAOYSA-N 0.000 claims 1
- DCYAMJKCSOSBMS-UHFFFAOYSA-N 2-[1-[1-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1CC1=C(C)ON=C1C1=CC=CC=C1 DCYAMJKCSOSBMS-UHFFFAOYSA-N 0.000 claims 1
- MFFGJKOCHMECCI-UHFFFAOYSA-N 2-[1-[1-[1-(4-chlorophenyl)cyclopropanecarbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 MFFGJKOCHMECCI-UHFFFAOYSA-N 0.000 claims 1
- ABDIANTVODPYMB-UHFFFAOYSA-N 2-[1-[1-[2-(2,6-dichlorophenyl)acetyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound ClC1=CC=CC(Cl)=C1CC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 ABDIANTVODPYMB-UHFFFAOYSA-N 0.000 claims 1
- KHHTXXKIWBHJGR-UHFFFAOYSA-N 2-[1-[1-[2-fluoro-3-(trifluoromethyl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KHHTXXKIWBHJGR-UHFFFAOYSA-N 0.000 claims 1
- KBXFUEFOJIBZET-UHFFFAOYSA-N 2-[1-[1-[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KBXFUEFOJIBZET-UHFFFAOYSA-N 0.000 claims 1
- WCXNKZPHMSGZLR-UHFFFAOYSA-N 2-[1-[1-[2-fluoro-6-(trifluoromethyl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 WCXNKZPHMSGZLR-UHFFFAOYSA-N 0.000 claims 1
- HFEQYAZFGMQKFJ-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 HFEQYAZFGMQKFJ-UHFFFAOYSA-N 0.000 claims 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 claims 1
- LBVRXDKQQKTQEZ-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-4-(1,3-thiazol-2-yl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=C1C1=NC=CS1 LBVRXDKQQKTQEZ-UHFFFAOYSA-N 0.000 claims 1
- AJXWDVYAVCKCDI-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(C(F)(F)F)C(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 AJXWDVYAVCKCDI-UHFFFAOYSA-N 0.000 claims 1
- XSVNQCQIBLRIMT-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 XSVNQCQIBLRIMT-UHFFFAOYSA-N 0.000 claims 1
- BRPWITKVLIGDOF-UHFFFAOYSA-N 2-[1-[1-[3-methoxy-5-(trifluoromethyl)thiophene-2-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(C(F)(F)F)SC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1OC BRPWITKVLIGDOF-UHFFFAOYSA-N 0.000 claims 1
- SYGQFABGIWNLOM-UHFFFAOYSA-N 2-[1-[1-[4-(1,3-benzoxazol-2-yl)-3-fluorobenzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C=1C=C(C=2OC3=CC=CC=C3N=2)C(F)=CC=1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 SYGQFABGIWNLOM-UHFFFAOYSA-N 0.000 claims 1
- NZFKMGISVBMCOH-UHFFFAOYSA-N 2-[1-[1-[4-(3,4-difluorophenyl)-3-fluorobenzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=C(F)C(F)=CC=C1C1=CC=C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C=C1F NZFKMGISVBMCOH-UHFFFAOYSA-N 0.000 claims 1
- NUWQMLMLMCAVNH-UHFFFAOYSA-N 2-[1-[1-[4-(4-chlorophenyl)cyclohexanecarbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C1CCC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 NUWQMLMLMCAVNH-UHFFFAOYSA-N 0.000 claims 1
- GPSJSZFVOZXEMY-UHFFFAOYSA-N 2-[1-[1-[4-chloro-6-(trifluoromethyl)pyridine-2-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC(Cl)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 GPSJSZFVOZXEMY-UHFFFAOYSA-N 0.000 claims 1
- VVYVGDLVYMCRNH-UHFFFAOYSA-N 2-[1-[1-[4-fluoro-3-(1,3-thiazol-2-yl)benzoyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C=C1C1=NC=CS1 VVYVGDLVYMCRNH-UHFFFAOYSA-N 0.000 claims 1
- GCOHIGJKONXAEP-UHFFFAOYSA-N 2-[1-[1-[5-chloro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=NC(C(F)(F)F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1Cl GCOHIGJKONXAEP-UHFFFAOYSA-N 0.000 claims 1
- PKGGGRQJYMCPGJ-UHFFFAOYSA-N 2-[1-[1-[5-chloro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=C2NC=CC2=C1C(=C1)C=NN1C(C1)(CC#N)CN1C(CC1)CCN1C(=O)C1=CC(C(F)(F)F)=NC=C1Cl PKGGGRQJYMCPGJ-UHFFFAOYSA-N 0.000 claims 1
- IPKHOEYJXDDGSU-UHFFFAOYSA-N 2-[1-[1-[5-chloro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=NC(C(F)(F)F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1Cl IPKHOEYJXDDGSU-UHFFFAOYSA-N 0.000 claims 1
- JDKXQCYZSUBGIZ-UHFFFAOYSA-N 2-[1-[1-[5-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=C(C(F)(F)F)C=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 JDKXQCYZSUBGIZ-UHFFFAOYSA-N 0.000 claims 1
- YOBVURQQUZGHKI-UHFFFAOYSA-N 2-[1-[1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 YOBVURQQUZGHKI-UHFFFAOYSA-N 0.000 claims 1
- PCGBJEYCFKNAOO-UHFFFAOYSA-N 2-[1-[1-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 PCGBJEYCFKNAOO-UHFFFAOYSA-N 0.000 claims 1
- KNFPQTAYABQSAR-UHFFFAOYSA-N 2-[1-[1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(C(F)(F)F)=CC=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KNFPQTAYABQSAR-UHFFFAOYSA-N 0.000 claims 1
- SDTSBTIPOZYKOI-UHFFFAOYSA-N 2-[1-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 SDTSBTIPOZYKOI-UHFFFAOYSA-N 0.000 claims 1
- CNRAJWHVWNRGKO-UHFFFAOYSA-N 2-[1-[1-[[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=C(Cl)C=CC(C(F)(F)F)=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 CNRAJWHVWNRGKO-UHFFFAOYSA-N 0.000 claims 1
- OABGQFBUWWQHEH-UHFFFAOYSA-N 2-[1-[1-[[4-(oxadiazol-4-yl)phenyl]methyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1C(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CN1C(CC1)CCN1CC(C=C1)=CC=C1C1=CON=N1 OABGQFBUWWQHEH-UHFFFAOYSA-N 0.000 claims 1
- LGHGBHSECRINRE-UHFFFAOYSA-N 2-[3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]-1-[1-(2,3,4-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=C(F)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 LGHGBHSECRINRE-UHFFFAOYSA-N 0.000 claims 1
- FGQCUYHMTAQIHB-UHFFFAOYSA-N 2-[3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]-1-[1-(2,3,6-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)=C1F FGQCUYHMTAQIHB-UHFFFAOYSA-N 0.000 claims 1
- MKLXXIKQPHGDKB-UHFFFAOYSA-N 2-[3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]-1-[1-(thiophene-2-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CS1 MKLXXIKQPHGDKB-UHFFFAOYSA-N 0.000 claims 1
- CRFDRUXXZMHGKJ-UHFFFAOYSA-N 2-[3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]-1-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)=C1 CRFDRUXXZMHGKJ-UHFFFAOYSA-N 0.000 claims 1
- BVSSQCPOTRJYOO-UHFFFAOYSA-N 2-[3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-1-[1-[2-(trifluoromethyl)pyrimidine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=NC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=N1 BVSSQCPOTRJYOO-UHFFFAOYSA-N 0.000 claims 1
- ABSQBBVXFSWQRK-UHFFFAOYSA-N 2-[3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CN=C2NC=CC2=C1C(=C1)C=NN1C(C1)(CC#N)CN1C(CC1)CCN1C(=O)C1=CC=NC(C(F)(F)F)=C1F ABSQBBVXFSWQRK-UHFFFAOYSA-N 0.000 claims 1
- MXLXKGHDGPYVBC-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC2=CC=CC=C2CC1C(=O)N(CC1)CCC1N(C1)CC1(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 MXLXKGHDGPYVBC-UHFFFAOYSA-N 0.000 claims 1
- KFPMZDVXEHVPEQ-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(2,3,4-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=C(F)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KFPMZDVXEHVPEQ-UHFFFAOYSA-N 0.000 claims 1
- ZTIHJYLZSFDTNN-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(2,3,6-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1F ZTIHJYLZSFDTNN-UHFFFAOYSA-N 0.000 claims 1
- WWYPEOYWKHWVHB-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(2,4,6-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC(F)=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 WWYPEOYWKHWVHB-UHFFFAOYSA-N 0.000 claims 1
- UZQKOMLXZWMLBI-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(3,4,5-trifluorobenzoyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=C(F)C(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UZQKOMLXZWMLBI-UHFFFAOYSA-N 0.000 claims 1
- YVLLLRNKSYCVNR-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(quinoline-3-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CC=CC2=CC(C(N3CCC(CC3)N3CC(CC#N)(C3)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)=O)=CN=C21 YVLLLRNKSYCVNR-UHFFFAOYSA-N 0.000 claims 1
- YPFGMVKCTXWLSA-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(quinoline-6-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound N1=CC=CC2=CC(C(N3CCC(CC3)N3CC(CC#N)(C3)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)=O)=CC=C21 YPFGMVKCTXWLSA-UHFFFAOYSA-N 0.000 claims 1
- XYUPRVONXQPNQW-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(thiophene-2-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CS1 XYUPRVONXQPNQW-UHFFFAOYSA-N 0.000 claims 1
- MDGGDPWHLGOFJK-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-(thiophene-3-carbonyl)piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C=1C=CSC=1 MDGGDPWHLGOFJK-UHFFFAOYSA-N 0.000 claims 1
- XZRZKPSBFSPKKR-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[2-(2,4,6-trimethylphenyl)acetyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound CC1=CC(C)=CC(C)=C1CC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 XZRZKPSBFSPKKR-UHFFFAOYSA-N 0.000 claims 1
- SAZUZOSGAWOLCT-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1=NC(C(F)(F)F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 SAZUZOSGAWOLCT-UHFFFAOYSA-N 0.000 claims 1
- QFPGZAJRDFHPCE-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[2-(trifluoromethyl)pyrimidine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=NC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 QFPGZAJRDFHPCE-UHFFFAOYSA-N 0.000 claims 1
- UNNSPOJJWNTDJL-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UNNSPOJJWNTDJL-UHFFFAOYSA-N 0.000 claims 1
- JBSIYEBHEXXDEO-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 JBSIYEBHEXXDEO-UHFFFAOYSA-N 0.000 claims 1
- ANDNISDAHMIKRM-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[4-(trifluoromethyl)cyclohexanecarbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound C1CC(C(F)(F)F)CCC1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 ANDNISDAHMIKRM-UHFFFAOYSA-N 0.000 claims 1
- VUMNCGMFRHJYTP-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[6-(trifluoromethyl)pyrazine-2-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CN=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 VUMNCGMFRHJYTP-UHFFFAOYSA-N 0.000 claims 1
- CJLKPPIUSIMZOS-UHFFFAOYSA-N 2-[4-[3-(cyanomethyl)-3-[4-(5-cyano-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzene-1,4-dicarbonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)CCN1C(=O)C1=CC(C#N)=CC=C1C#N CJLKPPIUSIMZOS-UHFFFAOYSA-N 0.000 claims 1
- JOGNOKZDYQQWGP-UHFFFAOYSA-N 2-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzene-1,4-dicarbonitrile Chemical compound FC1=CN=C2NC=CC2=C1C(=C1)C=NN1C(C1)(CC#N)CN1C(CC1)CCN1C(=O)C1=CC(C#N)=CC=C1C#N JOGNOKZDYQQWGP-UHFFFAOYSA-N 0.000 claims 1
- QUQBYRCFKCEJMV-UHFFFAOYSA-N 2-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1=CC=CC=C1C#N QUQBYRCFKCEJMV-UHFFFAOYSA-N 0.000 claims 1
- GLEMMHWKHUXFKW-UHFFFAOYSA-N 2-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC=C1C#N GLEMMHWKHUXFKW-UHFFFAOYSA-N 0.000 claims 1
- XLHKBHODXAZRNQ-UHFFFAOYSA-N 2-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorophenyl]benzonitrile Chemical compound FC1=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=C1C1=CC=CC=C1C#N XLHKBHODXAZRNQ-UHFFFAOYSA-N 0.000 claims 1
- YJEJBPFDRLCYHJ-UHFFFAOYSA-N 2-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]piperidin-1-yl]-6-methylpyridine-3-carbonitrile Chemical compound CC1=CC=C(C#N)C(N2CCC(CC2)C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 YJEJBPFDRLCYHJ-UHFFFAOYSA-N 0.000 claims 1
- BVRPIDFGHQWSEA-UHFFFAOYSA-N 2-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CN1C(CC1)CCN1CC1=CC=CC=C1C#N BVRPIDFGHQWSEA-UHFFFAOYSA-N 0.000 claims 1
- HNMWPCVAYLJGTP-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-5-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)=C1 HNMWPCVAYLJGTP-UHFFFAOYSA-N 0.000 claims 1
- FDEXCMVSAHLSDJ-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC(C#N)=C1 FDEXCMVSAHLSDJ-UHFFFAOYSA-N 0.000 claims 1
- YYAPXQDMPDKSGM-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-5-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)=C1 YYAPXQDMPDKSGM-UHFFFAOYSA-N 0.000 claims 1
- LHNVUHXNJWADTE-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1=CC=CC(C#N)=C1 LHNVUHXNJWADTE-UHFFFAOYSA-N 0.000 claims 1
- WQNFTZOVCTXIKW-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-5-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WQNFTZOVCTXIKW-UHFFFAOYSA-N 0.000 claims 1
- DWVCQDZWHRLWOJ-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-6-(dimethylamino)-2-fluorobenzonitrile Chemical compound FC1=C(C#N)C(N(C)C)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 DWVCQDZWHRLWOJ-UHFFFAOYSA-N 0.000 claims 1
- PKGPSAJBWSEWFD-UHFFFAOYSA-N 3-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=CC(C#N)=C1 PKGPSAJBWSEWFD-UHFFFAOYSA-N 0.000 claims 1
- FYATUSPSVPIDFE-UHFFFAOYSA-N 3-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorophenyl]benzonitrile Chemical compound FC1=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=C1C1=CC=CC(C#N)=C1 FYATUSPSVPIDFE-UHFFFAOYSA-N 0.000 claims 1
- ISESDXMWPTZKRT-UHFFFAOYSA-N 3-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-2-methylpiperidin-1-yl]methyl]-6-(dimethylamino)-2-fluorobenzonitrile Chemical compound CC1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1CC1=CC=C(N(C)C)C(C#N)=C1F ISESDXMWPTZKRT-UHFFFAOYSA-N 0.000 claims 1
- XUXDYTVAGSFHAN-UHFFFAOYSA-N 3-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]-6-(dimethylamino)-2-fluorobenzonitrile Chemical compound FC1=C(C#N)C(N(C)C)=CC=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 XUXDYTVAGSFHAN-UHFFFAOYSA-N 0.000 claims 1
- FYAIMVZLZTXMKX-UHFFFAOYSA-N 3-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CN1C(CC1)CCN1CC1=CC=CC(C#N)=C1 FYAIMVZLZTXMKX-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- FSKSWJIKOXAUAG-UHFFFAOYSA-N 4-[1-[1-[1-(4-cyano-2,6-difluorobenzoyl)piperidin-4-yl]-3-(cyanomethyl)azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound FC1=CC(C#N)=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)CC1 FSKSWJIKOXAUAG-UHFFFAOYSA-N 0.000 claims 1
- GTLANSQVNGYHGV-UHFFFAOYSA-N 4-[1-[1-[1-[5-chloro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-(cyanomethyl)azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1=NC(C(F)(F)F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)=C1Cl GTLANSQVNGYHGV-UHFFFAOYSA-N 0.000 claims 1
- NNAQUTDWXVJFOU-UHFFFAOYSA-N 4-[1-[3-(cyanomethyl)-1-(1-methylsulfonylpiperidin-4-yl)azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1CN(S(=O)(=O)C)CCC1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)C1 NNAQUTDWXVJFOU-UHFFFAOYSA-N 0.000 claims 1
- YPBCAHLQNNVWRJ-UHFFFAOYSA-N 4-[1-[3-(cyanomethyl)-1-[1-(2,5-dibromobenzoyl)piperidin-4-yl]azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound BrC1=CC=C(Br)C(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)=C1 YPBCAHLQNNVWRJ-UHFFFAOYSA-N 0.000 claims 1
- RRYCDJCSQSCPRC-UHFFFAOYSA-N 4-[1-[3-(cyanomethyl)-1-[1-(3,5-dibromobenzoyl)piperidin-4-yl]azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound BrC1=CC(Br)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)=C1 RRYCDJCSQSCPRC-UHFFFAOYSA-N 0.000 claims 1
- JTTSQSZBURMEKM-UHFFFAOYSA-N 4-[1-[3-(cyanomethyl)-1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)CC1 JTTSQSZBURMEKM-UHFFFAOYSA-N 0.000 claims 1
- LQWSVVIZJGQULY-UHFFFAOYSA-N 4-[1-[3-(cyanomethyl)-1-[1-[5-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound FC1=CN=C(C(F)(F)F)C=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)CC1 LQWSVVIZJGQULY-UHFFFAOYSA-N 0.000 claims 1
- SMBNMMYAWCDVRU-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]-n-(2,4-difluorophenyl)piperidine-1-carboxamide Chemical compound FC1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 SMBNMMYAWCDVRU-UHFFFAOYSA-N 0.000 claims 1
- DIGORXYVKOGFRB-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]-n-(2-cyanophenyl)piperidine-1-carboxamide Chemical compound C1CC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)NC1=CC=CC=C1C#N DIGORXYVKOGFRB-UHFFFAOYSA-N 0.000 claims 1
- ZQACZRQHHVMEPR-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]-n-[2-methyl-6-(trifluoromethyl)pyridin-3-yl]piperidine-1-carboxamide Chemical compound CC1=NC(C(F)(F)F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 ZQACZRQHHVMEPR-UHFFFAOYSA-N 0.000 claims 1
- XNOLKJMVOAOTTR-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]-n-[3-(trifluoromethyl)pyridin-2-yl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CN=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 XNOLKJMVOAOTTR-UHFFFAOYSA-N 0.000 claims 1
- LLIGFJOQLAYYDQ-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]-n-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 LLIGFJOQLAYYDQ-UHFFFAOYSA-N 0.000 claims 1
- CEQNCOJTCZYRDY-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 CEQNCOJTCZYRDY-UHFFFAOYSA-N 0.000 claims 1
- NRVQXFWCSBQJFN-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 NRVQXFWCSBQJFN-UHFFFAOYSA-N 0.000 claims 1
- GZRILVVLQYYHSP-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-(1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)NC1=NC=CS1 GZRILVVLQYYHSP-UHFFFAOYSA-N 0.000 claims 1
- HVPCXDYPRNQTOB-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-[3-(trifluoromethyl)pyridin-4-yl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CN=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 HVPCXDYPRNQTOB-UHFFFAOYSA-N 0.000 claims 1
- RZUCZMLSGAQMJN-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 RZUCZMLSGAQMJN-UHFFFAOYSA-N 0.000 claims 1
- CUOCVTUXQIDETI-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-propan-2-ylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC(C)C)CCC1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C1 CUOCVTUXQIDETI-UHFFFAOYSA-N 0.000 claims 1
- DTBOOLGABAYLNQ-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-thiophen-3-ylpiperidine-1-carboxamide Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)NC=1C=CSC=1 DTBOOLGABAYLNQ-UHFFFAOYSA-N 0.000 claims 1
- KEHZDNCDFYPSEL-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-3,5-difluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 KEHZDNCDFYPSEL-UHFFFAOYSA-N 0.000 claims 1
- RIWCWLNUBTVERO-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2C=C(C=C2)C=2C=3C=CNC=3N=CN=2)CC1 RIWCWLNUBTVERO-UHFFFAOYSA-N 0.000 claims 1
- UNRMWZNDXAAOPZ-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CC1 UNRMWZNDXAAOPZ-UHFFFAOYSA-N 0.000 claims 1
- HGGAVZKADJWQQA-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)=C1 HGGAVZKADJWQQA-UHFFFAOYSA-N 0.000 claims 1
- WIQUSYCVUZBNNO-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 WIQUSYCVUZBNNO-UHFFFAOYSA-N 0.000 claims 1
- DRNBGYHGJOXBLC-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1S(=O)(=O)C1=CC=C(C#N)C=C1 DRNBGYHGJOXBLC-UHFFFAOYSA-N 0.000 claims 1
- RGYNREPMIHXCLK-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 RGYNREPMIHXCLK-UHFFFAOYSA-N 0.000 claims 1
- YPLABYJEJAJYPG-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-3,5-difluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 YPLABYJEJAJYPG-UHFFFAOYSA-N 0.000 claims 1
- VQMJZRQFPBZMRK-UHFFFAOYSA-N 4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C1=CC=C(C#N)C=C1 VQMJZRQFPBZMRK-UHFFFAOYSA-N 0.000 claims 1
- IBCNFSKVJJJJTL-UHFFFAOYSA-N 4-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorophenyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC(C=2C(=CC(=CC=2)C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)F)=C1 IBCNFSKVJJJJTL-UHFFFAOYSA-N 0.000 claims 1
- GPRJSSVUXDUPQT-UHFFFAOYSA-N 4-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorophenyl]benzonitrile Chemical compound FC1=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=C1C1=CC=C(C#N)C=C1 GPRJSSVUXDUPQT-UHFFFAOYSA-N 0.000 claims 1
- PLLMBQKYTKFQCB-UHFFFAOYSA-N 4-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]phenyl]benzonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C(C=C1)=CC=C1C1=CC=C(C#N)C=C1 PLLMBQKYTKFQCB-UHFFFAOYSA-N 0.000 claims 1
- NKXFHCWKMCHHDI-UHFFFAOYSA-N 4-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 NKXFHCWKMCHHDI-UHFFFAOYSA-N 0.000 claims 1
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 claims 1
- AOWQKMUADIXHEC-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(5-cyano-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzene-1,3-dicarbonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2C#N)CCN1C(=O)C1=CC(C#N)=CC(C#N)=C1 AOWQKMUADIXHEC-UHFFFAOYSA-N 0.000 claims 1
- XBHXTQHOUVDXHH-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2F)CC1 XBHXTQHOUVDXHH-UHFFFAOYSA-N 0.000 claims 1
- CSOSMWZRCXSRBB-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]benzene-1,3-dicarbonitrile Chemical compound FC1=CN=C2NC=CC2=C1C(=C1)C=NN1C(C1)(CC#N)CN1C(CC1)CCN1C(=O)C1=CC(C#N)=CC(C#N)=C1 CSOSMWZRCXSRBB-UHFFFAOYSA-N 0.000 claims 1
- IEIADWBVIAXTRN-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]sulfonyl-2-(dimethylamino)benzonitrile Chemical compound C1=C(C#N)C(N(C)C)=CC=C1S(=O)(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 IEIADWBVIAXTRN-UHFFFAOYSA-N 0.000 claims 1
- GCCGLVIEPMZLEX-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-(dimethylamino)benzonitrile Chemical compound C1=C(C#N)C(N(C)C)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 GCCGLVIEPMZLEX-UHFFFAOYSA-N 0.000 claims 1
- JHMOGMFDLJUAQS-UHFFFAOYSA-N 5-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 JHMOGMFDLJUAQS-UHFFFAOYSA-N 0.000 claims 1
- QANLPBPAEYOOIU-UHFFFAOYSA-N 5-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]-2-fluorobenzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1CN1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 QANLPBPAEYOOIU-UHFFFAOYSA-N 0.000 claims 1
- DLTGIMBYEKKUNN-UHFFFAOYSA-N 6-[4-[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidine-1-carbonyl]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound C1CC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCN1C(=O)C(CC1)CCN1C1=CC=C(C#N)C=N1 DLTGIMBYEKKUNN-UHFFFAOYSA-N 0.000 claims 1
- BYQIUKQYAARDHH-UHFFFAOYSA-N 6-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]-2-methoxypyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OC)=NC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 BYQIUKQYAARDHH-UHFFFAOYSA-N 0.000 claims 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- WTBDJVKVKHXNIN-UHFFFAOYSA-N n-[4-[[4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]piperidin-1-yl]methyl]pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound C1=NC(NC(=O)C(C)(C)C)=CC(CN2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WTBDJVKVKHXNIN-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31258810P | 2010-03-10 | 2010-03-10 | |
| US61/312,588 | 2010-03-10 | ||
| US41560210P | 2010-11-19 | 2010-11-19 | |
| US61/415,602 | 2010-11-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017112574A Division JP6318291B2 (ja) | 2010-03-10 | 2017-06-07 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070257A Division JP2020114868A (ja) | 2010-03-10 | 2020-04-09 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018118992A JP2018118992A (ja) | 2018-08-02 |
| JP2018118992A5 true JP2018118992A5 (enExample) | 2019-07-11 |
Family
ID=44065466
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557194A Active JP5858484B2 (ja) | 2010-03-10 | 2011-03-09 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2015241393A Active JP6158282B2 (ja) | 2010-03-10 | 2015-12-10 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2017112574A Active JP6318291B2 (ja) | 2010-03-10 | 2017-06-07 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2018070780A Pending JP2018118992A (ja) | 2010-03-10 | 2018-04-02 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2020070257A Pending JP2020114868A (ja) | 2010-03-10 | 2020-04-09 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2023081459A Active JP7592784B2 (ja) | 2010-03-10 | 2023-05-17 | Jak1阻害剤としてのピペリジン-4-イルアゼチジン誘導体 |
| JP2024201971A Pending JP2025019114A (ja) | 2010-03-10 | 2024-11-20 | Jak1阻害剤としてのピペリジン-4-イルアゼチジン誘導体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557194A Active JP5858484B2 (ja) | 2010-03-10 | 2011-03-09 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2015241393A Active JP6158282B2 (ja) | 2010-03-10 | 2015-12-10 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2017112574A Active JP6318291B2 (ja) | 2010-03-10 | 2017-06-07 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070257A Pending JP2020114868A (ja) | 2010-03-10 | 2020-04-09 | Jak1阻害剤としてのピペリジン−4−イルアゼチジン誘導体 |
| JP2023081459A Active JP7592784B2 (ja) | 2010-03-10 | 2023-05-17 | Jak1阻害剤としてのピペリジン-4-イルアゼチジン誘導体 |
| JP2024201971A Pending JP2025019114A (ja) | 2010-03-10 | 2024-11-20 | Jak1阻害剤としてのピペリジン-4-イルアゼチジン誘導体 |
Country Status (37)
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| ES2487542T3 (es) * | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| WO2010135621A1 (en) * | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| PE20120493A1 (es) | 2009-06-29 | 2012-05-20 | Incyte Corp | Pirimidinonas como inhibidores de pi3k |
| WO2011028685A1 (en) * | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| PH12012502296B1 (en) | 2010-05-21 | 2017-10-06 | Incyte Holdings Corp | Topical formulation for a jak inhibitor |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
| TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| KR20230038593A (ko) | 2011-09-02 | 2023-03-20 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2640911T3 (es) | 2011-09-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2013173720A1 (en) * | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US20150203453A1 (en) | 2012-10-02 | 2015-07-23 | Epitherapeutics Aps | Inhibitors of histone demethylases |
| US9181271B2 (en) | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| PE20151157A1 (es) | 2012-11-15 | 2015-08-19 | Incyte Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| HUE050215T2 (hu) | 2013-01-15 | 2020-11-30 | Incyte Holdings Corp | Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek |
| JP6514117B2 (ja) | 2013-02-27 | 2019-05-15 | エピセラピューティクス アーペーエス | ヒストン脱メチル化酵素の阻害剤 |
| LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| ES2955137T3 (es) | 2013-03-14 | 2023-11-28 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| JP6305510B2 (ja) | 2013-03-19 | 2018-04-04 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン |
| AU2014234908B2 (en) | 2013-03-19 | 2017-08-17 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors |
| WO2014146246A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| US20160045498A1 (en) * | 2013-04-04 | 2016-02-18 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating diseases characterized by excessive wnt signalling |
| HRP20231048T1 (hr) | 2013-05-17 | 2023-12-22 | Incyte Holdings Corporation | Derivati bipirazola kao jak inhibitori |
| UA120499C2 (uk) * | 2013-08-07 | 2019-12-26 | Інсайт Корпорейшн | Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1 |
| SG11201601119XA (en) * | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| CR20160449A (es) * | 2014-02-28 | 2016-12-20 | Incyte Corp | Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos |
| MA39984B1 (fr) | 2014-04-08 | 2020-12-31 | Incyte Corp | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CA2957947A1 (en) * | 2014-08-27 | 2016-03-03 | Gilead Sciences, Inc. | Compounds and methods for inhibiting histone demethylases |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| PH12017501538B1 (en) | 2015-02-27 | 2024-02-14 | Incyte Holdings Corp | Salts of p13k inhibitor and processes for their preparation |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| SG10201913989QA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SI3371190T1 (sl) | 2015-11-06 | 2022-08-31 | Incyte Corporation | Heterociklične spojine kot inhibitorji PI3K gama |
| HK1250707B (zh) | 2015-12-11 | 2020-07-03 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
| WO2017120194A1 (en) | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| US10822339B2 (en) * | 2016-01-26 | 2020-11-03 | Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
| US20190086392A1 (en) | 2016-03-21 | 2019-03-21 | Inserm (Institut National De La Sante Et De La Recherch Medicale) | Methods for diagnosis and treatment of solar lentigo |
| PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| US11397145B2 (en) * | 2016-08-24 | 2022-07-26 | The University Of Melbourne | Diagnostic methods and device |
| GB201617871D0 (en) * | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US20180153922A1 (en) | 2016-12-06 | 2018-06-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease |
| MX390625B (es) | 2017-01-17 | 2025-03-19 | Astrazeneca Ab | Inhibidores selectivos de jak1. |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| CN109422753B (zh) * | 2017-09-03 | 2021-12-31 | 上海美志医药科技有限公司 | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 |
| US10633387B2 (en) | 2017-09-27 | 2020-04-28 | Incyte Corporation | Salts of TAM inhibitors |
| SI3697789T1 (sl) | 2017-10-18 | 2022-04-29 | Incyte Corporation | Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama |
| CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
| IL276302B2 (en) * | 2018-01-30 | 2023-11-01 | Incyte Corp | Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one) |
| CN118490690A (zh) * | 2018-02-16 | 2024-08-16 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
| CN118161607A (zh) | 2018-03-08 | 2024-06-11 | 诺华股份有限公司 | 抗p-选择素抗体的用途 |
| US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| SMT202400306T1 (it) * | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| AU2019252259A1 (en) | 2018-04-13 | 2020-12-03 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CN112469418A (zh) | 2018-06-01 | 2021-03-09 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| SI3813800T1 (sl) | 2018-06-29 | 2025-07-31 | Incyte Corporation | Formulacije zaviralca axl/mer |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| KR101992148B1 (ko) | 2018-11-30 | 2019-06-25 | 한승훈 | 안전벨트의 꼬임방지장치 |
| CN113692278A (zh) | 2018-12-19 | 2021-11-23 | 因赛特公司 | 用于治疗胃肠道疾病的jak1途径抑制剂 |
| JP2022515272A (ja) * | 2018-12-24 | 2022-02-17 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
| KR20210137087A (ko) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제 |
| EP3939979A4 (en) | 2019-03-14 | 2022-04-06 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| TW202102222A (zh) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
| WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| TW202123941A (zh) | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | Mdm2抑制劑用於治療骨髓纖維化之用途 |
| WO2021053490A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12203942B2 (en) | 2019-10-10 | 2025-01-21 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CR20220280A (es) | 2019-11-22 | 2022-09-02 | Incyte Corp | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 |
| JP2023516441A (ja) | 2020-03-06 | 2023-04-19 | インサイト・コーポレイション | Axl/mer阻害剤及びpd-1/pd-l1阻害剤を含む併用療法 |
| IL297437A (en) | 2020-05-13 | 2022-12-01 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| PE20231102A1 (es) | 2020-06-02 | 2023-07-19 | Incyte Corp | Procesos para preparar un inhibidor de jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2021329301A1 (en) | 2020-08-18 | 2023-04-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
| KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
| WO2022074600A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| MD4255442T2 (ro) | 2020-12-04 | 2025-08-31 | Incyte Corp | Inhibitor al JAK cu un analog al vitaminei D pentru tratamentul bolilor de piele |
| US11957661B2 (en) | 2020-12-08 | 2024-04-16 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of vitiligo |
| CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| TWI820622B (zh) | 2021-03-04 | 2023-11-01 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
| CN117098765A (zh) * | 2021-03-15 | 2023-11-21 | 奇斯药制品公司 | 作为詹纳斯激酶抑制剂的杂环衍生物 |
| IL308216A (en) | 2021-05-03 | 2024-01-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| CN118317946A (zh) | 2021-07-12 | 2024-07-09 | 因赛特公司 | 用于制备巴瑞替尼的方法和中间体 |
| CN114149437A (zh) * | 2021-12-24 | 2022-03-08 | 安徽大学 | 一种吡咯并嘧啶五元氮杂环衍生物及其制备方法和用途 |
| JP2025527297A (ja) | 2022-08-05 | 2025-08-20 | インサイト・コーポレイション | Jak阻害剤を使用した蕁麻疹の処置 |
| US20240307353A1 (en) | 2023-03-16 | 2024-09-19 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆(香港)生物科技有限公司 | Sarm1調節子、其製劑及用途 |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (309)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| CA2067221C (en) | 1989-10-11 | 1997-04-15 | Yasuji Sakuma | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4位に環状アミノ基を有するピロロ[2,3―d]ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| JP4010563B2 (ja) | 1995-07-05 | 2007-11-21 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 殺菌・殺カビ性のピリミジノン類 |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| WO1997036587A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | A method of treating cancer |
| CA2251955A1 (en) | 1996-04-18 | 1997-10-23 | Nancy E. Kohl | A method of treating cancer |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| JP2001524079A (ja) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | ガンの治療方法 |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US5919779A (en) | 1997-08-11 | 1999-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP1090009A2 (en) | 1998-06-04 | 2001-04-11 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| CZ20004727A3 (cs) | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
| CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
| PT1109534E (pt) | 1998-09-10 | 2003-06-30 | Nycomed Danmark As | Composicoes farmaceuticas de farmacos de libertacao rapida |
| FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| WO2000051614A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| WO2000063168A1 (en) | 1999-04-16 | 2000-10-26 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6915718B2 (en) * | 1999-09-02 | 2005-07-12 | United Parts Fhs Automobil Systeme Gmbh | Selector handle in a motor vehicle |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| EP1221443B1 (en) * | 1999-10-13 | 2004-09-01 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| AU777911B2 (en) | 1999-12-10 | 2004-11-04 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| WO2001047922A2 (en) | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| ATE250924T1 (de) | 2000-04-07 | 2003-10-15 | Medidom Lab | Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel |
| AU4878601A (en) | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| IL153115A0 (en) | 2000-06-16 | 2003-06-24 | Curis Inc | Angiogenesis-modulating compositions and uses |
| US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| EP1295607B9 (en) | 2000-06-23 | 2011-10-05 | Mitsubishi Tanabe Pharma Corporation | Antitumor effect potentiators |
| UA74370C2 (uk) | 2000-06-26 | 2005-12-15 | Пфайзер Продактс Інк. | Піроло(2,3-d)піримідинові сполуки як імуносупресори |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| EP1343781B1 (en) | 2000-12-05 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| US6884804B2 (en) | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US6852727B2 (en) | 2001-08-01 | 2005-02-08 | Merck & Co., Inc. | Benzimisazo[4,5-f]isoquinolinone derivatives |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| TWI302836B (en) | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| CN1582272A (zh) | 2001-11-30 | 2005-02-16 | 帝人株式会社 | 制备5-(3-氰基苯基)-3-甲酰基苯甲酸化合物的方法 |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| EA007156B1 (ru) | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Замедленно высвобождающие лекарственные композиции гвайфенезина |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR20100120243A (ko) | 2002-05-07 | 2010-11-12 | 피시비다 유에스 인코포레이티드 | 약물 전달 장치를 형성하는 공정 |
| IL165264A0 (en) | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Protein kinase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| EP1535934A4 (en) | 2002-06-26 | 2005-11-02 | Idemitsu Kosan Co | HYDROGENATED COPOLYMER, METHOD FOR THE PRODUCTION THEREOF AND THIS CONTAINING HOTMELT ADHESIVE COMPOSITION |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| JPWO2004007472A1 (ja) | 2002-07-10 | 2005-11-17 | 小野薬品工業株式会社 | Ccr4アンタゴニストおよびその医薬用途 |
| JP2006502183A (ja) | 2002-09-20 | 2006-01-19 | アルコン,インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| ATE371656T1 (de) | 2002-11-04 | 2007-09-15 | Vertex Pharma | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| BR0316487A (pt) | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| JP2006522124A (ja) | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| ES2357801T3 (es) | 2003-10-24 | 2011-04-29 | Santen Pharmaceutical Co., Ltd. | Agente terapéutico para trastorno queratoconjuntival. |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| BRPI0416909A (pt) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
| SG133602A1 (en) | 2003-12-17 | 2007-07-30 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| MY139808A (en) | 2003-12-19 | 2009-10-30 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
| AU2004303602C1 (en) | 2003-12-23 | 2009-05-28 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| US20050165029A1 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005089502A2 (en) | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| WO2005105988A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Crystal structure of human jak3 kinase domain complex and binding pockets thereof |
| EP2363149A1 (en) | 2004-05-03 | 2011-09-07 | Novartis AG | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| CA2566158A1 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| BRPI0511978A (pt) | 2004-06-10 | 2008-01-22 | Irm Llc | compostos e composições como inibidores de proteìnas quinases |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| EP2325184A1 (en) | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2582985A1 (en) | 2004-10-13 | 2006-04-20 | Jin-Jun Liu | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
| US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| WO2006065916A1 (en) | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006077499A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited | Chemical compounds |
| ES2320487T3 (es) | 2005-02-03 | 2009-05-22 | Vertex Pharmaceuticals, Inc. | Pirrolopirimidinas utiles como inhibidores de proteina quinasas. |
| US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| RU2383545C2 (ru) | 2005-03-15 | 2010-03-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
| ES2401192T3 (es) | 2005-09-30 | 2013-04-17 | Vertex Pharmceuticals Incorporated | Deazapurinas útiles como inhibidores de janus cinasas |
| US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| KR101315574B1 (ko) | 2005-10-14 | 2013-10-08 | 스미또모 가가꾸 가부시끼가이샤 | 히드라지드 화합물 및 이의 살충 용도 |
| EP2388259A1 (en) | 2005-10-28 | 2011-11-23 | AstraZeneca AB | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| DK1951684T3 (en) | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
| NZ568182A (en) | 2005-11-21 | 2010-08-27 | Novartis Ag | Neuroendocrine tumor treatment using MTOR inhibitors |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| KR20080083680A (ko) | 2005-12-23 | 2008-09-18 | 스미스클라인 비참 코포레이션 | 오로라 키나제의 아자인돌 억제제 |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| WO2007090141A2 (en) | 2006-02-01 | 2007-08-09 | Smithkline Beecham Corporation | Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| KR20080099334A (ko) | 2006-02-24 | 2008-11-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 메토프로롤 숙시네이트 서방정 및 이의 제조 방법 |
| KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| JP5099005B2 (ja) | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| RU2008143361A (ru) * | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
| EP2059515A2 (en) | 2006-04-12 | 2009-05-20 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| WO2007135461A2 (en) | 2006-05-18 | 2007-11-29 | Bayer Healthcare Ag | Pharmaceutical compositions comprising implitapide and methods of using same |
| US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| BRPI0713187A2 (pt) | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| WO2008016123A1 (en) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| ATE517868T1 (de) | 2006-08-16 | 2011-08-15 | Boehringer Ingelheim Int | Pyrazinverbindungen, ihre verwendung und herstellungsverfahren |
| EP2081888A1 (en) | 2006-09-08 | 2009-07-29 | Novartis AG | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| US7750007B2 (en) | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| CA2669991C (en) | 2006-11-22 | 2016-01-26 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
| CA2672903C (en) | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
| JP5374492B2 (ja) | 2007-04-03 | 2013-12-25 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害薬としてのイミダゾ[1,2−a]ピリジン化合物 |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| KR101258316B1 (ko) | 2007-07-11 | 2013-04-30 | 화이자 인코포레이티드 | 안구 건조증 치료용 약학 조성물 및 방법 |
| EA201000113A1 (ru) | 2007-08-01 | 2010-08-30 | Пфайзер Инк. | Пиразольные соединения |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| PT3133080T (pt) | 2008-01-18 | 2018-11-16 | Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleósidos de 7-deazapurina citostáticos inovadores |
| NZ587165A (en) | 2008-02-04 | 2012-03-30 | Mercury Therapeutics Inc | Ampk modulators |
| AR070531A1 (es) | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| CN102015686B (zh) | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
| US8344144B2 (en) | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| KR102080429B1 (ko) | 2008-06-26 | 2020-02-21 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
| RU2493157C2 (ru) | 2008-08-20 | 2013-09-20 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| US8735424B2 (en) | 2008-09-02 | 2014-05-27 | Novartis Ag | Bicyclic kinase inhibitors |
| PT2344474E (pt) | 2008-09-02 | 2015-12-28 | Novartis Ag | Derivados de picolinamida como inibidores de cinase |
| CA2735782A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2350054A4 (en) | 2008-10-17 | 2012-03-28 | Merck Canada Inc | AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| EP2470534A4 (en) | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2475659B1 (en) | 2009-09-08 | 2015-10-28 | F.Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| CA2777114C (en) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| NZ598907A (en) | 2009-10-20 | 2014-03-28 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| US8671402B2 (en) | 2009-11-09 | 2014-03-11 | Bank Of America Corporation | Network-enhanced control of software updates received via removable computer-readable medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| EP2504031A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | ANTI-IL-6 ANTIBODIES AND THEIR USE |
| EP2506852A4 (en) | 2009-12-04 | 2013-06-19 | Univ Texas | INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION |
| CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| CN102712640A (zh) | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| AU2011217961B2 (en) | 2010-02-18 | 2016-05-05 | Incyte Holdings Corporation | Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘 |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| PH12012502296B1 (en) | 2010-05-21 | 2017-10-06 | Incyte Holdings Corp | Topical formulation for a jak inhibitor |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
| US20130237493A1 (en) | 2010-09-30 | 2013-09-12 | Portola Pharmaceuticals, Inc. | Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| SG10201509919UA (en) | 2010-12-03 | 2016-01-28 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
| ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| CA2876306C (en) | 2012-06-15 | 2024-02-20 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| CA2879603A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| US9181271B2 (en) | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| PE20151157A1 (es) | 2012-11-15 | 2015-08-19 | Incyte Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
| LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
| HRP20231048T1 (hr) | 2013-05-17 | 2023-12-22 | Incyte Holdings Corporation | Derivati bipirazola kao jak inhibitori |
| UA120499C2 (uk) | 2013-08-07 | 2019-12-26 | Інсайт Корпорейшн | Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1 |
| SG11201601119XA (en) | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| CR20160449A (es) | 2014-02-28 | 2016-12-20 | Incyte Corp | Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos |
| MA39984B1 (fr) | 2014-04-08 | 2020-12-31 | Incyte Corp | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| EP4233870A3 (en) | 2014-05-28 | 2024-01-24 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| CA3129096A1 (en) | 2019-02-06 | 2020-08-13 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2011
- 2011-03-09 SM SM20180137T patent/SMT201800137T1/it unknown
- 2011-03-09 EP EP15195698.4A patent/EP3050882B1/en not_active Revoked
- 2011-03-09 HU HUE11711709A patent/HUE028723T2/en unknown
- 2011-03-09 NO NO15195698A patent/NO3050882T3/no unknown
- 2011-03-09 RS RS20160205A patent/RS54823B1/sr unknown
- 2011-03-09 SG SG2012064457A patent/SG183551A1/en unknown
- 2011-03-09 TW TW109116080A patent/TWI766281B/zh active
- 2011-03-09 MX MX2018002077A patent/MX364636B/es unknown
- 2011-03-09 JP JP2012557194A patent/JP5858484B2/ja active Active
- 2011-03-09 TW TW100107955A patent/TWI531572B/zh active
- 2011-03-09 NZ NZ602313A patent/NZ602313A/en unknown
- 2011-03-09 PT PT151956984T patent/PT3050882T/pt unknown
- 2011-03-09 TW TW107139196A patent/TWI694826B/zh active
- 2011-03-09 ES ES11711709T patent/ES2569539T3/es active Active
- 2011-03-09 CA CA2792508A patent/CA2792508C/en active Active
- 2011-03-09 KR KR1020187030015A patent/KR20180117206A/ko not_active Ceased
- 2011-03-09 EP EP20158754.0A patent/EP3715347B1/en active Active
- 2011-03-09 AU AU2011224484A patent/AU2011224484A1/en not_active Abandoned
- 2011-03-09 MX MX2012010344A patent/MX336932B/es active IP Right Grant
- 2011-03-09 KR KR1020127026216A patent/KR101857680B1/ko active Active
- 2011-03-09 ES ES15195698.4T patent/ES2662588T3/es active Active
- 2011-03-09 KR KR1020217023315A patent/KR102354472B1/ko active Active
- 2011-03-09 PE PE2012001467A patent/PE20130038A1/es active IP Right Grant
- 2011-03-09 HR HRP20160326TT patent/HRP20160326T1/hr unknown
- 2011-03-09 DK DK11711709.3T patent/DK2545045T3/en active
- 2011-03-09 EP EP17211097.5A patent/EP3354652B1/en active Active
- 2011-03-09 SI SI201131892T patent/SI3354652T1/sl unknown
- 2011-03-09 RS RS20180368A patent/RS57219B1/sr unknown
- 2011-03-09 SI SI201130747A patent/SI2545045T1/sl unknown
- 2011-03-09 EP EP11711709.3A patent/EP2545045B1/en active Active
- 2011-03-09 TW TW105101410A patent/TWI592413B/zh active
- 2011-03-09 EP EP21213769.9A patent/EP4036088B1/en active Active
- 2011-03-09 PH PH12015502575A patent/PH12015502575A1/en unknown
- 2011-03-09 LT LTEP17211097.5T patent/LT3354652T/lt unknown
- 2011-03-09 HU HUE15195698A patent/HUE037077T2/hu unknown
- 2011-03-09 DK DK17211097.5T patent/DK3354652T3/da active
- 2011-03-09 US US13/043,986 patent/US8765734B2/en active Active
- 2011-03-09 ES ES20158754T patent/ES2908412T3/es active Active
- 2011-03-09 PH PH1/2012/501768A patent/PH12012501768A1/en unknown
- 2011-03-09 ES ES17211097T patent/ES2796377T3/es active Active
- 2011-03-09 MX MX2019005232A patent/MX380755B/es unknown
- 2011-03-09 SI SI201131432T patent/SI3050882T1/en unknown
- 2011-03-09 CN CN201180023757.7A patent/CN102985417B/zh active Active
- 2011-03-09 TW TW111114548A patent/TWI850648B/zh active
- 2011-03-09 PL PL15195698T patent/PL3050882T3/pl unknown
- 2011-03-09 WO PCT/US2011/027665 patent/WO2011112662A1/en not_active Ceased
- 2011-03-09 MX MX2017006392A patent/MX354212B/es unknown
- 2011-03-09 DK DK15195698.4T patent/DK3050882T3/en active
- 2011-03-09 KR KR1020227001841A patent/KR20220015492A/ko not_active Withdrawn
- 2011-03-09 RS RS20200725A patent/RS60680B1/sr unknown
- 2011-03-09 MX MX2016001708A patent/MX347851B/es unknown
- 2011-03-09 KR KR1020207008092A patent/KR102172742B1/ko active Active
- 2011-03-09 HU HUE17211097A patent/HUE049914T2/hu unknown
- 2011-03-09 EA EA201290894A patent/EA030376B1/ru unknown
- 2011-03-09 SM SM20200373T patent/SMT202000373T1/it unknown
- 2011-03-09 MY MYPI2012003994A patent/MY175156A/en unknown
- 2011-03-09 KR KR1020207030868A patent/KR102283091B1/ko active Active
- 2011-03-09 PT PT172110975T patent/PT3354652T/pt unknown
- 2011-03-09 EP EP24165623.0A patent/EP4400172A3/en active Pending
- 2011-03-09 AR ARP110100737A patent/AR081315A1/es active IP Right Grant
- 2011-03-09 PL PL11711709T patent/PL2545045T3/pl unknown
- 2011-03-09 LT LTEP15195698.4T patent/LT3050882T/lt unknown
- 2011-03-09 PL PL17211097T patent/PL3354652T3/pl unknown
- 2011-03-09 BR BR112012022513A patent/BR112012022513A2/pt not_active Application Discontinuation
- 2011-03-09 ME MEP-2016-41A patent/ME02386B/me unknown
- 2011-03-09 TW TW106118905A patent/TWI643857B/zh active
- 2011-03-09 ES ES21213769T patent/ES2982015T3/es active Active
- 2011-03-09 KR KR1020187013055A patent/KR101911697B1/ko active Active
-
2012
- 2012-09-06 IL IL221823A patent/IL221823A/en active IP Right Grant
- 2012-09-10 CL CL2012002501A patent/CL2012002501A1/es unknown
- 2012-09-14 CO CO12158921A patent/CO6602158A2/es unknown
- 2012-10-03 ZA ZA2012/07420A patent/ZA201207420B/en unknown
- 2012-10-03 EC ECSP12012218 patent/ECSP12012218A/es unknown
- 2012-10-08 CR CR20120510A patent/CR20120510A/es unknown
- 2012-11-16 MY MYPI2016000078A patent/MY192255A/en unknown
-
2014
- 2014-05-28 US US14/289,121 patent/US9464088B2/en active Active
-
2015
- 2015-12-10 JP JP2015241393A patent/JP6158282B2/ja active Active
-
2016
- 2016-03-24 SM SM201600085T patent/SMT201600085B/it unknown
- 2016-10-07 US US15/288,641 patent/US9999619B2/en active Active
-
2017
- 2017-06-07 JP JP2017112574A patent/JP6318291B2/ja active Active
-
2018
- 2018-03-09 ME MEP-2018-86A patent/ME03002B/me unknown
- 2018-04-02 JP JP2018070780A patent/JP2018118992A/ja active Pending
- 2018-04-05 HR HRP20180552TT patent/HRP20180552T1/hr unknown
- 2018-04-16 CY CY20181100397T patent/CY1120154T1/el unknown
- 2018-06-01 US US15/995,323 patent/US10695337B2/en active Active
-
2020
- 2020-04-09 JP JP2020070257A patent/JP2020114868A/ja active Pending
- 2020-05-19 US US16/878,281 patent/US11285140B2/en active Active
- 2020-07-10 HR HRP20201086TT patent/HRP20201086T1/hr unknown
- 2020-07-22 CY CY20201100671T patent/CY1123175T1/el unknown
-
2022
- 2022-02-17 US US17/674,237 patent/US20230043959A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081459A patent/JP7592784B2/ja active Active
-
2024
- 2024-11-20 JP JP2024201971A patent/JP2025019114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018118992A5 (enExample) | ||
| JP2013522214A5 (enExample) | ||
| HRP20160326T1 (hr) | Derivati piperidin-4-il azetidina kao inhibitori jak1 | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2018530591A5 (enExample) | ||
| KR101859400B1 (ko) | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤 | |
| JP2016523911A5 (enExample) | ||
| JP2020526556A5 (enExample) | ||
| JP2013527173A5 (enExample) | ||
| JP2019530695A5 (enExample) | ||
| JP2014518214A5 (enExample) | ||
| JP2008519765A5 (enExample) | ||
| HRP20160539T1 (hr) | Antagonisti trpv4 | |
| JP2017500364A5 (enExample) | ||
| JP2015522002A5 (enExample) | ||
| HRP20120281T1 (hr) | Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3 | |
| EP1000055A1 (en) | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | |
| HRP20220096T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| JP2013508404A5 (enExample) | ||
| JP2014528446A5 (enExample) | ||
| JP2007523208A5 (enExample) | ||
| JP2013528591A5 (enExample) | ||
| JP2013545744A5 (enExample) | ||
| JP2020515575A5 (enExample) | ||
| JP2020527560A5 (enExample) |